March 16, 2025 — Santa Clara, CA
At the 2025 Precision Medicine World Conference (PMWC), experts from Pfizer and Data4Cure came together to present their joint efforts in transforming pharmaceutical R&D using artificial intelligence and knowledge graph technologies.
Dr. Paul Rejto, Vice President of Discovery Technologies at Pfizer, outlined the pressing challenges in oncology research—particularly the need to extract meaningful insights from thousands of studies, both internal and public. He emphasized how the collaboration with Data4Cure is designed to tackle this issue through:
- Systematic data analysis across diverse datasets,
- Real-time integration of findings into a continuously updated biomedical knowledge graph,
- Contextual interpretation of study results to support comparison and decision-making,
- And the application of large language models (LLMs) and AI to make this knowledge easily accessible to researchers across the organization.
These capabilities, he noted, aim to create an iterative learning loop to refine hypotheses, accelerate discovery, and drive more informed decision-making in drug development.
On the technology side, Dr. Janusz Dutkowski, CEO of Data4Cure, presented the capabilities of the Biomedical Intelligence Cloud platform. This includes:
- A DataHub for semantic integration of structured and unstructured biomedical data,
- An App Engine for rapid analytics and reporting,
- A dynamic knowledge graph that evolves with every integrated study,
- And a suite of AI tools, including foundation models and LLMs, that help turn complex biological data into actionable insights.
Through this collaboration, Pfizer is leveraging Data4Cure’s infrastructure to manage and extract insights from a wealth of biomedical information, enabling faster and more scalable innovation across R&D.
This partnership illustrates a broader industry shift toward data-driven innovation, where AI tools not only accelerate research but also democratize access to insights across global scientific teams.
By